Oncternal Therapeutics is a biopharmaceutical company engaged in the discovery, development and commercialization medicines to treat medical conditions, including stress urinary incontinence and prostate cancer. Co. is focused on the further development of selective androgen receptor modulators (SARMs), including its primary product candidate, enobosarm (GTx-024). SARMs is a class of drugs that has the potential to treat serious medical conditions such as stress urinary incontinence. Co. is also evaluating enobosarm and other compounds in its SARM portfolio for indications outside of oncology.